nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR1B—attention deficit hyperactivity disorder	0.258	0.323	CbGaD
Atomoxetine—SLC6A3—attention deficit hyperactivity disorder	0.233	0.292	CbGaD
Atomoxetine—SLC6A4—attention deficit hyperactivity disorder	0.175	0.218	CbGaD
Atomoxetine—HTR2A—attention deficit hyperactivity disorder	0.134	0.168	CbGaD
Atomoxetine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.00818	0.132	CbGeAlD
Atomoxetine—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00492	0.0791	CbGeAlD
Atomoxetine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00435	0.07	CbGeAlD
Atomoxetine—NPY1R—forebrain—attention deficit hyperactivity disorder	0.00299	0.048	CbGeAlD
Atomoxetine—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00261	0.0421	CbGeAlD
Atomoxetine—HTR6—forebrain—attention deficit hyperactivity disorder	0.0021	0.0338	CbGeAlD
Atomoxetine—NPY1R—nervous system—attention deficit hyperactivity disorder	0.00162	0.0261	CbGeAlD
Atomoxetine—NPY1R—central nervous system—attention deficit hyperactivity disorder	0.00156	0.0251	CbGeAlD
Atomoxetine—HTR1B—forebrain—attention deficit hyperactivity disorder	0.00127	0.0204	CbGeAlD
Atomoxetine—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00126	0.0202	CbGeAlD
Atomoxetine—NPY1R—brain—attention deficit hyperactivity disorder	0.00124	0.0199	CbGeAlD
Atomoxetine—HTR1D—forebrain—attention deficit hyperactivity disorder	0.00123	0.0197	CbGeAlD
Atomoxetine—HTR2C—forebrain—attention deficit hyperactivity disorder	0.00121	0.0195	CbGeAlD
Atomoxetine—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00115	0.0185	CbGeAlD
Atomoxetine—HTR6—nervous system—attention deficit hyperactivity disorder	0.00114	0.0184	CbGeAlD
Atomoxetine—HTR6—central nervous system—attention deficit hyperactivity disorder	0.0011	0.0177	CbGeAlD
Atomoxetine—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.00107	0.0172	CbGeAlD
Atomoxetine—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.00104	0.0167	CbGeAlD
Atomoxetine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00101	0.0163	CbGeAlD
Atomoxetine—HTR6—brain—attention deficit hyperactivity disorder	0.000872	0.014	CbGeAlD
Atomoxetine—HTR1B—midbrain—attention deficit hyperactivity disorder	0.000836	0.0135	CbGeAlD
Atomoxetine—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.000829	0.0133	CbGeAlD
Atomoxetine—HTR1D—midbrain—attention deficit hyperactivity disorder	0.00081	0.013	CbGeAlD
Atomoxetine—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000802	0.0129	CbGeAlD
Atomoxetine—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.00076	0.0122	CbGeAlD
Atomoxetine—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000687	0.0111	CbGeAlD
Atomoxetine—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000682	0.011	CbGeAlD
Atomoxetine—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000666	0.0107	CbGeAlD
Atomoxetine—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000662	0.0107	CbGeAlD
Atomoxetine—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000659	0.0106	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.000656	0.0106	CbGeAlD
Atomoxetine—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000642	0.0103	CbGeAlD
Atomoxetine—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000641	0.0103	CbGeAlD
Atomoxetine—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000635	0.0102	CbGeAlD
Atomoxetine—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.000625	0.0101	CbGeAlD
Atomoxetine—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000609	0.0098	CbGeAlD
Atomoxetine—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000602	0.00968	CbGeAlD
Atomoxetine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000555	0.00893	CbGeAlD
Atomoxetine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.00055	0.00885	CbGeAlD
Atomoxetine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.00053	0.00852	CbGeAlD
Atomoxetine—HTR1B—brain—attention deficit hyperactivity disorder	0.000525	0.00846	CbGeAlD
Atomoxetine—SLC6A3—brain—attention deficit hyperactivity disorder	0.000521	0.00839	CbGeAlD
Atomoxetine—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000515	0.00829	CbGeAlD
Atomoxetine—HTR1D—brain—attention deficit hyperactivity disorder	0.000509	0.00819	CbGeAlD
Atomoxetine—HTR2C—brain—attention deficit hyperactivity disorder	0.000504	0.00811	CbGeAlD
Atomoxetine—SLC6A4—brain—attention deficit hyperactivity disorder	0.000478	0.00769	CbGeAlD
Atomoxetine—SLC6A2—brain—attention deficit hyperactivity disorder	0.00042	0.00677	CbGeAlD
Atomoxetine—Phenoxybenzamine—ADRA2C—attention deficit hyperactivity disorder	0.000403	0.0657	CrCbGaD
Atomoxetine—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000402	0.00647	CbGeAlD
Atomoxetine—Diphenylpyraline—SLC6A3—attention deficit hyperactivity disorder	0.000373	0.0608	CrCbGaD
Atomoxetine—Duloxetine—SLC6A3—attention deficit hyperactivity disorder	0.000347	0.0567	CrCbGaD
Atomoxetine—Reboxetine—SLC6A4—attention deficit hyperactivity disorder	0.000338	0.0551	CrCbGaD
Atomoxetine—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000331	0.00532	CbGeAlD
Atomoxetine—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000318	0.00512	CbGeAlD
Atomoxetine—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000311	0.00501	CbGeAlD
Atomoxetine—Protriptyline—SLC6A4—attention deficit hyperactivity disorder	0.00031	0.0506	CrCbGaD
Atomoxetine—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000306	0.00493	CbGeAlD
Atomoxetine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000301	0.00485	CbGeAlD
Atomoxetine—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000295	0.00474	CbGeAlD
Atomoxetine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00029	0.00467	CbGeAlD
Atomoxetine—Benzatropine—SLC6A3—attention deficit hyperactivity disorder	0.000286	0.0466	CrCbGaD
Atomoxetine—Pseudoephedrine—MAOA—attention deficit hyperactivity disorder	0.000285	0.0465	CrCbGaD
Atomoxetine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000283	0.00456	CbGeAlD
Atomoxetine—Maprotiline—SLC6A3—attention deficit hyperactivity disorder	0.000265	0.0432	CrCbGaD
Atomoxetine—Duloxetine—SLC6A4—attention deficit hyperactivity disorder	0.00026	0.0424	CrCbGaD
Atomoxetine—HTR2A—brain—attention deficit hyperactivity disorder	0.000253	0.00407	CbGeAlD
Atomoxetine—Pseudoephedrine—SLC6A3—attention deficit hyperactivity disorder	0.000246	0.0401	CrCbGaD
Atomoxetine—Pseudoephedrine—ADRA2A—attention deficit hyperactivity disorder	0.000241	0.0393	CrCbGaD
Atomoxetine—CYP2D6—brain—attention deficit hyperactivity disorder	0.00023	0.0037	CbGeAlD
Atomoxetine—Fluoxetine—SLC6A4—attention deficit hyperactivity disorder	0.000212	0.0346	CrCbGaD
Atomoxetine—Modafinil—SLC6A3—attention deficit hyperactivity disorder	0.000212	0.0345	CrCbGaD
Atomoxetine—Duloxetine—HTR2A—attention deficit hyperactivity disorder	0.0002	0.0326	CrCbGaD
Atomoxetine—Maprotiline—DRD2—attention deficit hyperactivity disorder	0.000197	0.0321	CrCbGaD
Atomoxetine—Propranolol—HTR1B—attention deficit hyperactivity disorder	0.000191	0.0312	CrCbGaD
Atomoxetine—Pseudoephedrine—SLC6A4—attention deficit hyperactivity disorder	0.000184	0.03	CrCbGaD
Atomoxetine—Benzphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000183	0.0299	CrCbGaD
Atomoxetine—Benzphetamine—ADRA2A—attention deficit hyperactivity disorder	0.00018	0.0293	CrCbGaD
Atomoxetine—Phenoxybenzamine—ADRA2A—attention deficit hyperactivity disorder	0.000172	0.028	CrCbGaD
Atomoxetine—Fluoxetine—HTR2A—attention deficit hyperactivity disorder	0.000163	0.0266	CrCbGaD
Atomoxetine—Maprotiline—HTR2A—attention deficit hyperactivity disorder	0.000152	0.0248	CrCbGaD
Atomoxetine—Desipramine—SLC6A3—attention deficit hyperactivity disorder	0.000131	0.0214	CrCbGaD
Atomoxetine—Nortriptyline—SLC6A4—attention deficit hyperactivity disorder	0.000119	0.0194	CrCbGaD
Atomoxetine—Nortriptyline—DRD2—attention deficit hyperactivity disorder	0.000118	0.0193	CrCbGaD
Atomoxetine—Desipramine—SLC6A4—attention deficit hyperactivity disorder	9.79e-05	0.016	CrCbGaD
Atomoxetine—Desipramine—DRD2—attention deficit hyperactivity disorder	9.73e-05	0.0159	CrCbGaD
Atomoxetine—Nortriptyline—HTR2A—attention deficit hyperactivity disorder	9.14e-05	0.0149	CrCbGaD
Atomoxetine—Desipramine—HTR2A—attention deficit hyperactivity disorder	7.52e-05	0.0123	CrCbGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.14e-05	0.000545	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	7.13e-05	0.000543	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	7.1e-05	0.000542	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.09e-05	0.00054	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7.08e-05	0.00054	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	7.08e-05	0.00054	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	7.02e-05	0.000535	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	6.95e-05	0.00053	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.94e-05	0.000529	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.93e-05	0.000528	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—COMT—attention deficit hyperactivity disorder	6.92e-05	0.000528	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—MAOA—attention deficit hyperactivity disorder	6.87e-05	0.000524	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.87e-05	0.000524	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.81e-05	0.00052	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	6.73e-05	0.000513	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.69e-05	0.00051	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.67e-05	0.000509	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	6.64e-05	0.000506	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	6.58e-05	0.000502	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.44e-05	0.000491	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.42e-05	0.00049	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	6.38e-05	0.000486	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.37e-05	0.000486	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.31e-05	0.000481	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	6.28e-05	0.000479	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	6.27e-05	0.000478	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.27e-05	0.000478	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.24e-05	0.000476	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.24e-05	0.000476	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	6.21e-05	0.000473	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	6.2e-05	0.000473	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	6.19e-05	0.000472	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	6.17e-05	0.00047	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.14e-05	0.000468	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.13e-05	0.000468	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.06e-05	0.000462	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.91e-05	0.000451	CbGpPWpGaD
Atomoxetine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	5.84e-05	0.000445	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.79e-05	0.000442	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.77e-05	0.00044	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	5.77e-05	0.00044	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.64e-05	0.00043	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.59e-05	0.000426	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.5e-05	0.000419	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.45e-05	0.000416	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.43e-05	0.000414	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.43e-05	0.000414	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.41e-05	0.000413	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	5.39e-05	0.000411	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.37e-05	0.000409	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.3e-05	0.000404	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.26e-05	0.000401	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	5.19e-05	0.000396	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	5.15e-05	0.000393	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.13e-05	0.000391	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	5.12e-05	0.00039	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	5.07e-05	0.000386	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.06e-05	0.000386	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.03e-05	0.000383	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.01e-05	0.000382	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.01e-05	0.000382	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.97e-05	0.000379	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.95e-05	0.000377	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	4.94e-05	0.000377	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.91e-05	0.000375	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.87e-05	0.000371	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	4.85e-05	0.00037	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.81e-05	0.000367	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.81e-05	0.000367	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.77e-05	0.000364	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.77e-05	0.000364	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	4.77e-05	0.000364	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.76e-05	0.000363	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.74e-05	0.000361	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.73e-05	0.000361	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.73e-05	0.000361	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	4.71e-05	0.000359	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.71e-05	0.000359	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.67e-05	0.000356	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	4.66e-05	0.000355	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.65e-05	0.000355	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.57e-05	0.000348	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.43e-05	0.000338	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.4e-05	0.000335	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.39e-05	0.000335	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.33e-05	0.00033	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.31e-05	0.000328	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.3e-05	0.000328	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.29e-05	0.000327	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.29e-05	0.000327	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.27e-05	0.000326	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.26e-05	0.000325	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.22e-05	0.000322	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.22e-05	0.000322	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.19e-05	0.000319	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.18e-05	0.000319	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.18e-05	0.000319	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.17e-05	0.000318	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.16e-05	0.000318	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.14e-05	0.000315	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.13e-05	0.000315	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.11e-05	0.000313	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.11e-05	0.000313	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.1e-05	0.000313	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.1e-05	0.000312	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.05e-05	0.000309	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.02e-05	0.000307	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.02e-05	0.000307	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.01e-05	0.000306	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.99e-05	0.000304	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.95e-05	0.000301	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.91e-05	0.000298	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.9e-05	0.000297	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.88e-05	0.000296	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.87e-05	0.000295	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.85e-05	0.000294	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.83e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.8e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.79e-05	0.000289	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.78e-05	0.000288	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.77e-05	0.000287	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.75e-05	0.000286	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	3.73e-05	0.000285	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.72e-05	0.000284	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.69e-05	0.000281	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.68e-05	0.00028	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.65e-05	0.000278	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.54e-05	0.00027	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.52e-05	0.000269	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.51e-05	0.000268	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.5e-05	0.000267	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.49e-05	0.000266	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.42e-05	0.000261	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.26e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.21e-05	0.000244	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.19e-05	0.000243	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.17e-05	0.000242	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.17e-05	0.000241	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.16e-05	0.000241	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	3.12e-05	0.000238	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.11e-05	0.000237	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.11e-05	0.000237	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	3.1e-05	0.000236	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	3.08e-05	0.000235	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.07e-05	0.000234	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.05e-05	0.000232	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.05e-05	0.000232	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.96e-05	0.000226	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.92e-05	0.000223	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.9e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.87e-05	0.000219	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.86e-05	0.000218	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.84e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.83e-05	0.000216	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.82e-05	0.000215	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.79e-05	0.000212	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.77e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.75e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.74e-05	0.000209	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.72e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.7e-05	0.000206	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.7e-05	0.000206	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.7e-05	0.000206	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.66e-05	0.000203	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.65e-05	0.000202	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.64e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.59e-05	0.000198	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.57e-05	0.000196	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.56e-05	0.000195	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.54e-05	0.000193	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.49e-05	0.00019	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.48e-05	0.000189	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.47e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.45e-05	0.000187	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.45e-05	0.000187	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.42e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.4e-05	0.000183	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.38e-05	0.000181	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.36e-05	0.00018	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.31e-05	0.000176	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.3e-05	0.000175	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.28e-05	0.000174	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.26e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.25e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.24e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.24e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.23e-05	0.00017	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.22e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.2e-05	0.000168	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.17e-05	0.000166	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.15e-05	0.000164	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.12e-05	0.000162	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.09e-05	0.00016	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.08e-05	0.000159	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.07e-05	0.000157	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.02e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2e-05	0.000153	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.95e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.88e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.87e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.82e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.75e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.69e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.67e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.65e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.63e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.53e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.52e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.47e-05	0.000112	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	1.47e-05	0.000112	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.47e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.46e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.45e-05	0.00011	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.45e-05	0.00011	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	1.44e-05	0.00011	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.43e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.42e-05	0.000108	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.35e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.35e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.34e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.33e-05	0.000101	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.33e-05	0.000101	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.28e-05	9.73e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.23e-05	9.4e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.17e-05	8.93e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.12e-05	8.5e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.08e-05	8.22e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.07e-05	8.19e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.03e-05	7.82e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	8.88e-06	6.77e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	8.81e-06	6.72e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	8.81e-06	6.72e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.81e-06	6.72e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	8.67e-06	6.61e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	8.55e-06	6.52e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	8.17e-06	6.23e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	8.11e-06	6.18e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.06e-06	6.14e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.72e-06	5.89e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.66e-06	5.84e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.5e-06	5.72e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.04e-06	5.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.71e-06	5.11e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.69e-06	4.34e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	5.34e-06	4.07e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	5.3e-06	4.04e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.94e-06	3.77e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	3.81e-06	2.9e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	3.5e-06	2.67e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.29e-06	1.75e-05	CbGpPWpGaD
